Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell massBart Keymeulen, Daniël Pipeleers, Melanie Walter et al.|Diabetologia|2010Cited by 313
Health Literacy and Quality of Life in Young Adults From The Belgian Crohn's Disease Registry Compared to Type 1 Diabetes MellitusConstance Carels, Gigi Veereman, Danny De Looze et al.|Frontiers in Pediatrics|2021Cited by 10
Identification and characterisation of the dose response of otelixizumab in new onset type 1 diabetes patientsAntonio Napolitano, Bart Keymeulen, André van Maurik et al.|VUBIR (Vrije Universiteit Brussel)|2019Cited by 0